A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Have one of the following locally advanced or metastatic solid tumor malignancy withSMARCA4 (BRG1) alteration:

• Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)

• Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locallyadvanced and not suitable for definitive locoregional therapy, or metastaticwith presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.

• Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has thepresence of a known or likely loss of function alteration in SMARCA4 (BRG1) orloss of protein expression.

• Phase 1b expansion: Part C: Non-small Cell Lung Cancer (NSCLC) that is locallyadvanced and not suitable for definitive locoregional therapy, or metastaticwith presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.

• Prior Systemic Therapy Criteria:

• Phase 1a dose escalation and Phase 1b (Part B): Participants who received allstandard therapies for which the individual was deemed to be an appropriatecandidate by the treating Investigator; or the individual is refusing theremaining most appropriate standard of care treatment; or there is no standardtherapy available for the disease.

• Phase 1b expansion (Part A): Participants must have received at least one lineof therapy for advanced or metastatic disease.

• Phase 1b expansion (Part C): Participants may be treatment naïve or havereceived therapy for advanced or metastatic disease

• Measurability of disease

• Phase 1a dose escalation (excluding backfill): measurable or non-measurabledisease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECISTv1.1)

• Phase 1a backfill and Phase 1b expansion: Measurable disease required asdefined by RECIST v1.1

• Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion Criteria:

• Participants with known or likely loss of function alteration of SMARCA2 (BRM) ormalignancy with known association with SMARCA2 (BRM) alterations

• Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure maybe permitted for dose escalation)

• Participants with known or suspected history of untreated or uncontrolled centralnervous system (CNS) involvement

• Participants with history of increased risk of prolonged QT or significant arrythmia

• Significant cardiovascular disease

• Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment

• Participants who are pregnant, breastfeeding or plan to breastfeed or expecting toconceive or father children during study or within 6 months after the last dose ofstudy intervention

• Participants with history of active autoimmune diseases, history of allogenic stemcell/organ transplant or compromised immune system within past 2 years (Part C only)